Drugs / SOB100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07219940 | Dec 2025 → Dec 2026 expected | — | Shine-On Biomedical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOB100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07219940 ↗ |
| Target | HLA-G | “SOB100 is an engineered exosome designed to target cancer cells by binding to HLA-G.” PMID 42083744 ↗ May 2026 |